Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup
Reisa A. Sperling(Harvard University), Rachel Schindler(Pfizer (United States)), Clifford R. Jack(Mayo Clinic), H. Robert Brashear(Brigham and Women's Hospital), Michael Grundman(University of San Diego), Philip Scheltens(Amsterdam University Medical Centers), María C. Carrillo(Brigham and Women's Hospital), William Thies(Stroke Association), Sandra E. Black(Sunnybrook Health Science Centre), Howard Feldman(University of British Columbia), Steven M. Greenberg(Harvard University), Bradley T. Hyman(Harvard University), Martin M. Bednar(Pfizer (United States)), Eric Siemers(Eli Lilly (United States)), Ronald S. Black(Pfizer (United States)), Matthew P. Frosch(Harvard University)
Cited by 830
Related Papers
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|18.9k
An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest
|NeuroImage|2006|14.1k
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
|The Lancet Neurology|2013|5.4k